红字部分如何翻译
发布于 2020-04-11 · 浏览 1557 · IP 北京北京
这个帖子发布于 5 年零 30 天前，其中的信息可能已发生改变或有所发展。
In pure class V LN, no high-quality evidence has emerged over the last 7 years. MMF/MPA is recommended as first-choice at the same doses as in class III/IV disease. CY and CNI (especially TAC), the latter as monotherapy or combined with MMF, are alternative options.43 49
Similar to class III/IV LN, rituximab (RTX) is reserved for non-responders in class V LN (see below), although a recent RCT in idiopathic membranous nephropathy, which demonstrated short-term superiority over CsA, may justify a modification once similar data emerge in LN.50
红字部分如何翻译，
最后编辑于 2022-10-09 · 浏览 1557
9 收藏点赞
